{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:04:22Z","timestamp":1740146662766,"version":"3.37.3"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer GmbH","award":["WI 183749"],"award-info":[{"award-number":["WI 183749"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0234396","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:49:59Z","timestamp":1596649799000},"page":"e0234396","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Early conversion to a CNI-free immunosuppression with SRL after renal transplantation\u2014Long-term follow-up of a multicenter trial"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-3913","authenticated-orcid":true,"given":"Joachim","family":"Andrassy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Guba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Habicht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Fischereder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Pratschke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Pascher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina M.","family":"Heller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Banas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Hakenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-7329","authenticated-orcid":true,"given":"Thomas","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Meiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Kauke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the SMART-Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"issue":"Suppl 1","key":"pone.0234396.ref001","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/ajt.14557","article-title":"OPTN\/SRTR 2016 Annual Data Report: Kidney","volume":"18","author":"A Hart","year":"2018","journal-title":"Am J Transplant"},{"issue":"4","key":"pone.0234396.ref002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJMoa1204166","article-title":"Sirolimus and secondary skin-cancer prevention in kidney transplantation","volume":"367","author":"S Euvrard","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0234396.ref003","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/TP.0b013e3181e11798","article-title":"Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial","volume":"90","author":"M Guba","year":"2010","journal-title":"Transplantation"},{"issue":"8","key":"pone.0234396.ref004","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1111\/j.1600-6143.2009.02726.x","article-title":"Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation","volume":"9","author":"H Ekberg","year":"2009","journal-title":"Am J Transplant"},{"issue":"25","key":"pone.0234396.ref005","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"H Ekberg","year":"2007","journal-title":"N Engl J Med"},{"issue":"9768","key":"pone.0234396.ref006","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","article-title":"Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial","volume":"377","author":"K Budde","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"pone.0234396.ref007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1600-6143.2009.02615.x","article-title":"Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study","volume":"9","author":"Y Lebranchu","year":"2009","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0234396.ref008","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial","volume":"87","author":"FP Schena","year":"2009","journal-title":"Transplantation"},{"issue":"6","key":"pone.0234396.ref009","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/ndt\/gfx075","article-title":"Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial","volume":"32","author":"K Budde","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"pone.0234396.ref010","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/TP.0b013e3182848e03","article-title":"Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation","volume":"95","author":"D Cibrik","year":"2013","journal-title":"Transplantation"},{"issue":"6","key":"pone.0234396.ref011","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1600-6143.2005.00885.x","article-title":"A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients\u2014an interim analysis.","volume":"5","author":"R Kandaswamy","year":"2005","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0234396.ref012","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"J Sellares","year":"2012","journal-title":"Am J Transplant"},{"issue":"5","key":"pone.0234396.ref013","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"C Wiebe","year":"2012","journal-title":"Am J Transplant"},{"issue":"1","key":"pone.0234396.ref014","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/TP.0b013e3181e065de","article-title":"Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure","volume":"90","author":"RS Gaston","year":"2010","journal-title":"Transplantation"},{"issue":"8","key":"pone.0234396.ref015","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"C Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"pone.0234396.ref016","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1111\/j.1600-6143.2011.03961.x","article-title":"Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation","volume":"12","author":"L Liefeldt","year":"2012","journal-title":"Am J Transplant"},{"issue":"8","key":"pone.0234396.ref017","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1600-6143.2011.03637.x","article-title":"Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study","volume":"11","author":"Y Lebranchu","year":"2011","journal-title":"Am J Transplant"},{"issue":"7","key":"pone.0234396.ref018","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation","volume":"29","author":"J Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"pone.0234396.ref019","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1432-2277.2012.01432.x","article-title":"Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation","volume":"25","author":"M Guba","year":"2012","journal-title":"Transpl Int"},{"issue":"7","key":"pone.0234396.ref020","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1600-6143.2012.04036.x","article-title":"Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study","volume":"12","author":"Y Lebranchu","year":"2012","journal-title":"Am J Transplant"},{"key":"pone.0234396.ref021","article-title":"Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy","author":"C Sommerer","year":"2018","journal-title":"Am J Transplant"},{"issue":"6","key":"pone.0234396.ref022","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/j.1600-6143.2010.03129.x","article-title":"Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients","volume":"10","author":"H Tedesco Silva","year":"2010","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0234396.ref023","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study","volume":"6","author":"S Vitko","year":"2006","journal-title":"Am J Transplant"},{"issue":"10","key":"pone.0234396.ref024","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1111\/j.1600-6143.2012.04162.x","article-title":"Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation","volume":"12","author":"L Mjornstedt","year":"2012","journal-title":"Am J Transplant"},{"issue":"2","key":"pone.0234396.ref025","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"MI Lorber","year":"2005","journal-title":"Transplantation"},{"key":"pone.0234396.ref026","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/731426","article-title":"Comparable Renal Function at 6 Months with Tacrolimus Combined with Fixed-Dose Sirolimus or MMF: Results of a Randomized Multicenter Trial in Renal Transplantation","volume":"2010","author":"E Van Gurp","year":"2010","journal-title":"Journal of transplantation"},{"issue":"4","key":"pone.0234396.ref027","doi-asserted-by":"crossref","first-page":"e0194975","DOI":"10.1371\/journal.pone.0194975","article-title":"Effects of mTOR-Is on malignancy and survival following renal transplantation: A systematic review and meta-analysis of randomized trials with a minimum follow-up of 24 months","volume":"13","author":"S Wolf","year":"2018","journal-title":"PLoS One"},{"issue":"12","key":"pone.0234396.ref028","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/TP.0b013e3182708e56","article-title":"Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis","volume":"94","author":"J Andrassy","year":"2012","journal-title":"Transplantation"},{"key":"pone.0234396.ref029","first-page":"CD006750","article-title":"Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients","volume":"7","author":"KM Karpe","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"pone.0234396.ref030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/j.1600-6143.2011.03573.x","article-title":"The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients","volume":"11","author":"SM Flechner","year":"2011","journal-title":"Am J Transplant"},{"issue":"10","key":"pone.0234396.ref031","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/TP.0b013e318291a269","article-title":"A randomized, open-label study of sirolimus versus cyclosporine in primary de novo renal allograft recipients","volume":"95","author":"SM Flechner","year":"2013","journal-title":"Transplantation"},{"issue":"1\u20132","key":"pone.0234396.ref032","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.trim.2008.08.005","article-title":"Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes","volume":"20","author":"MS Anil Kumar","year":"2008","journal-title":"Transpl Immunol"},{"issue":"4","key":"pone.0234396.ref033","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/ajt.12166","article-title":"Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation","volume":"13","author":"TM Suszynski","year":"2013","journal-title":"Am J Transplant"},{"issue":"11","key":"pone.0234396.ref034","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1111\/j.1600-6143.2009.02799.x","article-title":"Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure","volume":"9","author":"G Einecke","year":"2009","journal-title":"Am J Transplant"},{"issue":"3","key":"pone.0234396.ref035","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/TP.0b013e31827d62e3","article-title":"Incidence and impact of de novo donor-specific alloantibody in primary renal allografts","volume":"95","author":"MJ Everly","year":"2013","journal-title":"Transplantation"},{"issue":"10","key":"pone.0234396.ref036","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes","volume":"91","author":"JE Cooper","year":"2011","journal-title":"Transplantation"},{"issue":"8","key":"pone.0234396.ref037","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/00007890-200210270-00025","article-title":"All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies","volume":"74","author":"PC Lee","year":"2002","journal-title":"Transplantation"},{"issue":"10","key":"pone.0234396.ref038","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1097\/TP.0b013e3181a44206","article-title":"Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts","volume":"87","author":"N Lachmann","year":"2009","journal-title":"Transplantation"},{"issue":"5","key":"pone.0234396.ref039","doi-asserted-by":"crossref","first-page":"e1002572","DOI":"10.1371\/journal.pmed.1002572","article-title":"Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis","volume":"15","author":"A Bouquegneau","year":"2018","journal-title":"PLoS medicine"},{"issue":"4","key":"pone.0234396.ref040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/tri.12887","article-title":"De novo donor-specific anti-HLA antibodies after kidney transplantation are associated with impaired graft outcome independently of their C1q-binding ability.","volume":"30","author":"T Kauke","year":"2017","journal-title":"Transpl Int"},{"issue":"1","key":"pone.0234396.ref041","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/TP.0b013e31821cdf0d","article-title":"Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection","volume":"92","author":"G Honger","year":"2011","journal-title":"Transplantation"},{"issue":"3","key":"pone.0234396.ref042","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/ctr.12127","article-title":"Incidence of donor-specific antibodies in kidney transplant patients following conversion to an everolimus-based calcineurin inhibitor-free regimen","volume":"27","author":"N Kamar","year":"2013","journal-title":"Clin Transplant"},{"issue":"1","key":"pone.0234396.ref043","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/TP.0000000000000965","article-title":"Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial","volume":"100","author":"EK Geissler","year":"2016","journal-title":"Transplantation"},{"issue":"7","key":"pone.0234396.ref044","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1111\/ajt.14186","article-title":"Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial","volume":"17","author":"JW de Fijter","year":"2017","journal-title":"Am J Transplant"},{"issue":"11","key":"pone.0234396.ref045","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1097\/TP.0000000000000748","article-title":"Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus","volume":"99","author":"TV de Sandes-Freitas","year":"2015","journal-title":"Transplantation"},{"issue":"6","key":"pone.0234396.ref046","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000475888","article-title":"Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus","volume":"45","author":"A Ferreira","year":"2017","journal-title":"American journal of nephrology"},{"issue":"1","key":"pone.0234396.ref047","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/tri.12656","article-title":"Eight-year results of the Spiesser study, a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation","volume":"29","author":"P Gatault","year":"2016","journal-title":"Transpl Int"},{"issue":"10","key":"pone.0234396.ref048","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1097\/TP.0000000000001012","article-title":"De Novo Anti-HLA DSA Characteristics and Subclinical Antibody-Mediated Kidney Allograft Injury","volume":"100","author":"T Yamamoto","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"pone.0234396.ref049","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/ajt.12952","article-title":"Five-year outcomes in kidney transplant patients converted from cyclosporine to everolimus: the randomized ZEUS study","volume":"15","author":"K Budde","year":"2015","journal-title":"Am J Transplant"},{"issue":"1","key":"pone.0234396.ref050","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/TP.0000000000001098","article-title":"Long-term Follow-up of Kidney Transplant Recipients in the Spare-the-Nephron-Trial","volume":"101","author":"MR Weir","year":"2017","journal-title":"Transplantation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T17:51:06Z","timestamp":1596649866000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0234396"}},"subtitle":[],"editor":[{"given":"Justyna","family":"Go\u0142\u0119biewska","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0234396","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,8,5]]}}}